Association of serum uric acid to high-density lipoprotein cholesterol ratio with all-cause mortality and cardiovascular disease mortality in patients with gout

血清尿酸与高密度脂蛋白胆固醇比值与痛风患者全因死亡率和心血管疾病死亡率的相关性

阅读:2

Abstract

BACKGROUND: The uric acid to high-density lipoprotein cholesterol ratio (UHR), a novel biomarker, has clinical value in diagnosing and evaluating metabolic syndrome, diabetes mellitus, and atherosclerosis. However, the relationship between UHR and mortality in gout patients is unknown.This study aimed to investigate UHR's link to all-cause and cardiovascular mortality in gout patients. METHODS: Based on NHANES data from 2007 to 2018, 1,479 gout patients who completed follow-up as of December 31, 2018 were included, and patients were divided into four groups using UHR, we analyzed the relationship between UHR and risk of death using Cox regression models, tested for nonlinear relationships with a restricted cubic spline, and assessed for population heterogeneity by stratifying by sex, age, and body mass index. RESULTS: The Kaplan-Meier analysis revealed that patients in the third UHR quartile (Q3) had the highest risk of death. The multivariate Cox regression analysis further confirmed that the overall mortality risk (HR: 1.44, 95% CI: 1.05-1.97) and cardiovascular mortality risk (HR: 1.73, 95% CI: 1.04-2.87) of this group were higher than those of the other groups. Restricted cubic spline analysis revealed a U-shaped association between UHR and all-cause mortality, with a significant positive correlation above a threshold of 21.6% (HR: 1.68, 95% CI: 1.26-2.24) and a linear positive correlation with cardiovascular mortality (HR: 1.40, 95% CI: 1.05-1.86). Subgroup analyses showed that these associations were consistent across age, BMI, and sex (p > 0.05 for interaction). CONCLUSION: This study confirms that UHR in gout patients has a U-shaped correlation with all-cause mortality and a linear correlation with cardiovascular mortality. Therefore, UHR may serve as a novel prognostic biomarker for mortality risk stratification in patients with gout.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。